Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

"Honestly, I'm quite alarmed by what we see in the U.S. now," Novo Nordisk President and CEO Lars Fruergaard Jorgensen told ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ...

Der er parkeringsplads lige bag biografen (Smedegades P-plads). Lørdag og søndag er der parkering uden tidsbegrænsning. Alle andre dage kan man holde der tre timer i tidsrummet 8-18. Kommer man efter ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...